908 Devices Inc.
Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.
AWM Investment Company, Inc. sold 18,000 indirectly-held shares of 908 Devices Inc. (MASS) at $11.52 ($0.21M total) on 2026-09-29.
AWM Investment Company, Inc. sold 25,000 indirectly-held shares of 908 Devices Inc. (MASS) at an average of $11.36 ($11.25–$11.36, $0.28M total) across 2 trades over 2026-09-23 to 2026-09-24.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MASS (908 Devices Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MASS coverage spans insider activity, earnings and financial news.
In the last 30 days, MASS insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($771K). The most active reporter was Kenneweg John, SVP, Sales & Product Marketing, with 3 filings. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
Strong revenue growth and raised guidance support continued upside.
The insider sale modestly increases supply pressure on MASS.
Insider sale of ~0.5% of holdings by a 10% owner.
Minor dilution of insider ownership; unlikely to move price materially.
Management highlights improving profitability, device shipment momentum, and new connected-services traction tied to NIRLAB and ProtectIR orders.
AlphAI scores every news story that mentions MASS with an AI model for sentiment and relevance, and aggregates insider trades from 908 Devices Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.
2 min readAWM Investment Company, Inc. sold 18,000 indirectly-held shares of 908 Devices Inc. (MASS) at $11.52 ($0.21M total) on 2026-09-29.
1 min readAWM Investment Company, Inc. sold 25,000 indirectly-held shares of 908 Devices Inc. (MASS) at an average of $11.36 ($11.25–$11.36, $0.28M total) across 2 trades over 2026-09-23 to 2026-09-24.
1 min readAWM Investment Company, Inc. sold 50,000 indirectly-held shares of 908 Devices Inc. (MASS) at an average of $10.60 ($10.52–$10.61, $0.53M total) across 2 trades over 2026-08-20 to 2026-08-21.
1 min read908 Devices (MASS) discussed its Q2 2026 performance and strategy. It said adjusted EBITDA loss was under $2 million, a 50% year-over-year improvement. The company acquired NIRLAB on May 6 and highlighted a $6 million ProtectIR order in July. It reported shipping 35 VipIR units in Q2 and 750+ FTIR devices over 24 months.
7 min read908 Devices (NASDAQ: MASS) reported Q2 operating expenses of $21.2M, down from $21.5M, and narrowed net loss from continuing operations to $11.9M. Adjusted EBITDA loss improved to $1.9M. Cash and marketable securities were $101.5M with no debt. The company raised 2026 revenue guidance to $68M-$70M and expects recurring revenue of $4.9M (31%).
7 min readKnopp Kevin J. (President and CEO) sold 149,013 shares of 908 Devices Inc. (MASS) at an average of $9.90 ($9.06–$10.16, $1.48M total) across 4 trades over 2026-08-10 to 2026-08-12 under a Rule 10b5-1 trading plan.
2 min readInvesting.com reports Stifel raised its price target for 908 Devices Inc. (NASDAQ:MASS) to $12 from $10 and kept a Buy rating after the company’s Q2 beat and an upward revision to full-year guidance. The stock trades near $10.01, with 91% YTD gains. Stifel forecasts 23% fiscal 2026 revenue growth and expects high-teens growth in 2027.
2 min read908 Devices Inc. (MASS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook Revenue increased 23% compared to prior year Updated full year 2026 outlook reflects 21% to 25% year-over-year growth BURLINGTON, Mass. – August 11, 2026 – 908
4 min readAWM Investment Company, Inc. sold 50,000 indirectly-held shares of 908 Devices Inc. (MASS) at $8.36 ($0.42M total) on 2026-08-04.
1 min read
